This high breakpoint signifies Zaynich’s strong potential to combat all clinically important, extremely drug-resistant Gram-negative pathogens in critically ill patients
Read More
This novel anti-infective, invented by Orchid Pharma, aims to address the rising threat of antimicrobial resistance (AMR) and has been approved for the treatment of complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP)
Read More
Data suggests that 1.2 million deaths in India are due to antimicrobial resistance (AMR), with an estimated 10 million deaths by 2050
Read More
India holds approximately 25 per cent of the global lung infection burden, and among adults over 50, one out of five cases of pneumococcal infections leads to mortality
Read More
Research has identified antibiotic-resistant pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug-resistant Salmonella, commonly present in food products, posing severe health risks
Read More
